Researchers develop FLASH ultra-high-dose rate radiation therapy beam for cancer treatment
A joint team of researchers from Radiation Oncology at Dartmouth s and Dartmouth-Hitchcock s Norris Cotton Cancer Center (NCCC), Dartmouth Engineering, and Dartmouth-Hitchcock s Department of Surgery have developed a method to convert a standard linear accelerator (LINAC), used for delivery of radiation therapy cancer treatment, to a FLASH ultra-high-dose rate radiation therapy beam. The work, entitled Electron FLASH Delivery at Treatment Room Isocenter for Efficient Reversible Conversion of a Clinical LINAC, is newly published online in the
International Journal of Radiation Oncology, Biology & Physics.
The exceptionally high dose rate is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the
A joint team of researchers from Radiation Oncology at Dartmouth’s and Dartmouth-Hitchcock’s Norris Cotton Cancer Center (NCCC), Dartmouth Engineering, and Dartmouth-Hitchcock’s Department of Surgery have developed a method to convert a standard linear accelerator (LINAC), used for delivery of radiation therapy cancer treatment, to a FLASH ultra-high-dose rate radiation therapy beam. The work, entitled “Electron FLASH Delivery at Treatment Room Isocenter for Efficient Reversible Conversion of a Clinical LINAC,” is newly published online in
International Journal of Radiation Oncology, Biology & Physics.
The exceptionally high dose rate is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, “FLASH.” “These high dose rates have been shown to pro
Alpha Tau Medical Announces Appointment of Peter Melnyk as New Board Member
USA - English
Share this article
Share this article
JERUSALEM, Jan. 12, 2021 /PRNewswire/ Alpha Tau Medical, the developer of breakthrough Alpha DaRT (Diffusing alpha-emitters Radiation Therapy), is pleased to announce the appointment of Peter Melnyk to its Board of Directors.
Mr. Melnyk is the CEO of Fortovia Therapeutics, a commercial stage, private equity-owned pharmaceutical company focused on oncology supportive care products. Prior to that, he held leading roles in sales, marketing, and business development in some of the top oncology franchises in the pharmaceutical and medical device industry. Recently, he was Chief Commercial Officer at Novocure, a cancer medical device company, where he built a global commercial platform and infrastructure to launch a new modality of anticancer technology based on the use of electric fields to inhibit tumor growth. He also developed business units in variou